These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 9273300

  • 1. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
    Guise S, Soubrouillard C, Blin O.
    Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
    [Abstract] [Full Text] [Related]

  • 2. Pathophysiology and treatment of negative symptoms.
    Villeneuve A.
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S53-8. PubMed ID: 7533052
    [Abstract] [Full Text] [Related]

  • 3. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.
    Keegan D.
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S46-52. PubMed ID: 7533051
    [Abstract] [Full Text] [Related]

  • 4. Pharmacotherapy of schizophrenia: a review.
    Sigmundson HK.
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S70-5. PubMed ID: 7533053
    [Abstract] [Full Text] [Related]

  • 5. [Psychopharmacologic approaches to schizophrenic psychoses].
    Giacardy-Paty M, Soubrouillard C, Blin O.
    Encephale; 1995 Jun; 21 Spec No 3():3-8. PubMed ID: 7628339
    [Abstract] [Full Text] [Related]

  • 6. [Neuroleptics and serotonin].
    Hery F, Hamon M.
    Encephale; 1993 Jun; 19(5):525-32. PubMed ID: 7905821
    [Abstract] [Full Text] [Related]

  • 7. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM, Shayegan DK.
    J Clin Psychiatry; 2003 Jun; 64 Suppl 19():6-12. PubMed ID: 14728084
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dopamine receptors and schizophrenia.
    Reynolds GP.
    Biochem Soc Trans; 1996 Feb; 24(1):202-5. PubMed ID: 8674664
    [No Abstract] [Full Text] [Related]

  • 11. Atypical antipsychotics: mechanism of action.
    Seeman P.
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [Abstract] [Full Text] [Related]

  • 12. [New chemotherapy approaches to psychoses].
    Olié JP, Baylé FJ.
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Central dopaminergic receptors and negative symptoms in schizophrenia].
    Martinot JL, Paillere-Martinot ML, Loc'h C, Aubin F, Dao-Castellana MH, Deslauriers AG, Syrota A, Lecrubier Y.
    Ann Med Psychol (Paris); 1992 Apr; 150(2-3):127-30. PubMed ID: 1343506
    [No Abstract] [Full Text] [Related]

  • 15. Pathophysiology of schizophrenia and the role of newer antipsychotics.
    Risch SC.
    Pharmacotherapy; 1996 Apr; 16(1 Pt 2):11-4. PubMed ID: 8778681
    [Abstract] [Full Text] [Related]

  • 16. [Recent developments in antipsychotic medication].
    Möller HJ.
    Schweiz Arch Neurol Psychiatr (1985); 1995 Apr; 146(5):230-9. PubMed ID: 8658104
    [Abstract] [Full Text] [Related]

  • 17. Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.
    Singh AN, Barlas C, Saeedi H, Mishra RK.
    J Psychiatry Neurosci; 2003 Jan; 28(1):39-47. PubMed ID: 12587849
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.